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Abstract
Objective: To evaluate the influence of periodontal therapy on DNA methylation in 
patients with chronic periodontitis as compared to healthy individuals.
Material and Methods: Twenty patients were enrolled into two groups: (i) 10 diag-
nosed as clinically healthy; and (ii) 10 diagnosed with chronic periodontitis. Clinical 
measures were recorded and gingival biopsies were harvested at baseline (both pa-
tient groups) and at 2 and 8 weeks post- baseline for diseased individuals. Molecular 
DNA methylation analysis was performed by pyrosequencing for the putative 
inflammation- associated genes LINE- 1, COX- 2, IFN- γ and TNF- α. Random- intercept 
linear regression models were applied to evaluate methylation levels across groups at 
baseline and the methylation changes over time in the diseased and normal tissues.
Results: Periodontal therapy did not influence gene expression methylation of TNF- α, 
IFN- γ and LINE- 1 levels at normal and periodontitis sites over time. However, it sig-
nificantly reduced COX- 2 methylation levels comparable to healthy individuals at both 
2 and 8 weeks post- treatment (p < .05).
Conclusions: Periodontal therapy resets the DNA methylation status of inflammatory 
gene for COX- 2 in patients with periodontal disease. DNA methylation levels of TNF- 
α, IFN- γ and LINE- 1 were sustained in periodontitis sites despite therapy. Future stud-
ies should consider an expanded panel of inflammatory genes over time. (ClinicalTrials.
gov NCT02835898).
K E Y W O R D S
biomarkers, DNA methylation, epigenetics, inflammatory genes, periodontal disease 
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1  | INTRODUCTION
Periodontitis is a destructive disease of the tooth- supporting tissues 
induced by bacterial biofilm (Van Dyke & van Winkelhoff, 2013) that 
eventually triggers an inflammatory host response influenced by en-
vironmental, genetic and epigenetic factors (Borrell & Papapanou, 
2005; Kornman, 2008; Takashiba & Naruishi, 2006). Of interest to this 
study, epigenetic modification can further regulate gene expression 
of an individual’s immune response (Schulz et al., 2016), and despite 
the well- established influence of epigenetic modification in cancer 
and inflammatory diseases (Adcock, Tsaprouni, Bhavsar, & Ito, 2007; El 
Gazzar, Yoza, Hu, Cousart, & McCall, 2007; Fitzpatrick & Wilson, 2003; 
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Ngollo et al., 2014) little is known in the context of oral health (Lod, 
Johansson, Abrahamsson, & Larsson, 2014). In general, epigenetics 
embodies the modifications of gene expression, without changing the 
DNA sequence (Adcock et al., 2007; Bird, 2002) through chemical al-
terations of DNA and associated proteins (Barros & Offenbacher, 2014) 
that evoke chromatin remodelling and a successive rapid inactivation 
or activation of genes (Larsson, Castilho, & Giannobile, 2015). Notably, 
such alterations occur through two major mechanisms in human cells 
(Shaw, 2006); DNA methylation and histone modifications (Wilson, 
2008) with the former offering a more stable form of gene regulation 
(Bäckdahl, Bushell, & Beck, 2009). Accordingly, most of the studies 
exploring the link between epigenetics and periodontal disease have 
investigated the changes in the DNA methylation of genes involved 
in the regulation of cytokine production, as these signalling mole-
cules play a key role in periodontal tissue breakdown; for reviews see: 
Barros & Offenbacher, 2014; Lod et al., 2014; Larsson et al., 2015;. 
Recent studies in experimental periodontitis have also demonstrated 
the activation of inflammatory routes including the NFκB signalling 
pathway by histone modifications (Martins et al., 2016). Several stud-
ies demonstrated a lower level of DNA methylation of genes express-
ing pro- inflammatory cytokines in patients with periodontitis, either 
chronic or aggressive, compared to those with a healthy periodontium 
(Andia et al., 2010; Ishida et al., 2012; Oliveira et al., 2009; Zhang, 
Crivello, et al., 2010). Nevertheless, hypermethylation has been also 
described for specific genes in the chronic state of periodontal dis-
ease, as a downregulatory mechanism to prevent unrestricted tissue 
destruction (Zhang, Barros, et al., 2010). Likewise, higher DNA methyl-
ation in chronic periodontitis has been also reported in recent studies 
(Kojima et al., 2016; Zhang et al., 2013). Although several epigenetic 
alterations have been described in periodontal disease, little is known 
about the efficacy of periodontal therapy in re- establishing normal 
DNA methylation levels in patients. The prospective positive effects 
of periodontal therapy on the methylation profile of DNA and specific 
genes came from the study of Andia et al. (2015) that found no change 
between healthy and periodontitis tissues after 3 months. These find-
ings suggest that periodontal therapy can influence epigenetic modi-
fications. However, variations in the methylation level between both 
groups were not assessed at baseline and samples of inflamed tissues 
were not investigated.
Based on these observations, we conducted a clinical study to 
monitor the changes in DNA methylation of long interspersed nuclear 
element- 1 (LINE- 1), cyclooxygenase- 2 (COX- 2), interferon gamma 
(IFN- γ) and tumour necrosis factor alpha (TNF- α) inflammatory genes 
in periodontitis patients following periodontal therapy in comparison 
with healthy subjects at both the site and patient levels.
2  | MATERIALS AND METHODS
This investigation was approved by the ethical committee of the 
University of Milan, Italy, and was conducted during the period be-
tween October 2015 and June 2016. This short- term, prospective co-
hort study is registered at ClinicalTrials.gov (Identifier: NCT02835898).
2.1 | Study participants and inclusion criteria
From the pool of patients attending a private dental practice in 
Piacenza—Italy, twenty individuals were enrolled equally in two 
groups: 10 healthy patients displaying a disease- free periodontium 
and 10 moderatepatients with chronic periodontitis, as the present 
clinical investigation is considered a pilot investigation. All participants 
were voluntarily enrolled into the study after explaining its objectives 
and obtaining their verbal and written informed consent.
Study participants fit the following inclusion criteria:
1. Patients 18 years of age or older.
2. Patients without any reported systemic diseases.
3. Non-smokers or ex-smokers who had quit smoking for at least one 
or more years prior to enrolment in the study.
4. Patients of Caucasian origin.
5. For the healthy group: patients who showed no clinical signs of gin-
gival inflammation or history of periodontitis were included. In this 
group,	periodontal	probing	depths	 (PPD)	 in	all	sites	were	≤3	mm,	
without any signs of tooth mobility, bleeding on probing (BOP) or 
clinical attachment loss (CAL).
6. For the periodontal disease group: patients diagnosed with chronic 
periodontitis according to the American Academy of Periodontology 
(AAP) Workshop definition (Armitage, 1999) were included. 
Patients in this group displayed a minimum of a single “healthy site” 
(PPD < 4 mm without signs of bleeding on probing, mobility or in-
flammation)	and	a	periodontitis	site	(PPD	≥	5	mm	with	bleeding	on	
probing at baseline) for subsequent biopsy harvesting.
The exclusion criteria were the following:
1. Pregnant patients.
2. Patients who reported the use of antibiotics and/or non-steroidal 
anti-inflammatory drugs (NSAIDs), for at least 1 month before en-
rolment in the study.
Clinical Relevance
Scientific rationale for the study: Little is known about the in-
fluence of periodontal therapy on DNA methylation levels in 
patients with chronic periodontitis.
Principal findings: Periodontal therapy is able to reset the lev-
els of COX- 2 methylation to compatible levels observed in 
healthy patients on the short- term. Methylation profile from 
normal tissues of patients with periodontitis suggests they 
might be more prone to periodontal tissue breakdown.
Practical implications: Local effects of the disease have an 
influence on the epigenetics of the tissues that may be mod-
ulated by the microbiota. Findings might help to better elu-
cidate disease development in healthy sites of patients with 
periodontitis.
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3. Patients who received periodontal therapy within the last 3 months 
prior to enrolment in the study.
2.2 | Study timeline and periodontal parameters
2.2.1 | Baseline
For periodontitis participants, periodontal probing depth (PPD), clini-
cal attachment level (CAL), bleeding on probing (BOP), full- mouth 
plaque score (FMPS) and full- mouth bleeding score (FMBS) were re-
corded at six sites around each tooth. As for healthy patients, only 
periodontal screening and recording (PSR) was registered, in accord-
ance with the principles of good clinical practice; the periodontal 
charting is completed when the patient presents with two or more 
sites	of	a	PD	≥	5	mm	(Tonetti	&	Claffey,	2005).
Next, gingival biopsies were obtained from the healthy patients 
during surgical removal of wisdom teeth, using a 3- mm diameter punch. 
In the periodontal disease group, biopsies were harvested from two 
sites: a normal site and a periodontitis site with the purpose to com-
pare methylation levels between both clinically distinct sites. Following 
biopsy harvest, patients with chronic periodontitis underwent conven-
tional periodontal therapy consisting of full- mouth scaling and root 
planing with ultrasonic and manual instruments. Chlorhexidine mouth-
wash (0.2%) was prescribed for daily use (twice daily for 20 days).
2.2.2 | Two and eight weeks after 
periodontal therapy
PPD, CAL & BOP, FMPS & FMBS were measured and gingival biopsies 
were harvested for the disease group only, from both a normal and a per-
iodontitis site, to analyse the influence of periodontal therapy on epige-
netic modifications as comparison to each time point. Two weeks point 
of time was selected to evaluate the early response to periodontal treat-
ment, while 8 weeks was chosen because the re- evaluation of periodon-
tal parameters after periodontal therapy varies between 4 and 8 weeks 
(ideally 4–6 weeks). However, 4 and 6 weeks points of time might be a 
little bit short for adequate stability of periodontal parameters, therefore, 
8 weeks was chosen as a reasonable point of time as a first re- evaluation 
following periodontal therapy (Segelnick & Weinberg, 2006).
In the periodontitis group, it was not possible to harvest biopsies 
from the same site at different points of time, therefore, tissue sam-
pling was carried out in a manner to match the clinical parameters at all 
points of time as the following: for healthy sites, PPD < 4 mm without 
bleeding on probing or signs of inflammation at all points of time. For 
periodontitis	sites,	PPD	≥	5	mm	with	bleeding	on	probing	at	baseline.	
For 2 and 8 weeks point of time, biopsies were harvested from sites of 
PPD	≥	5	mm	without	bleeding	on	probing	but	already	showed	BOP	at	
baseline, as documented in the periodontal chart.
A single calibrated examiner made the measurements and har-
vested the gingival biopsies (GR), while the same experienced dental 
hygienist (FP) performed the conventional periodontal therapy on all 
patients of the periodontitis group.
2.3 | Sample collection, DNA extraction and 
bisulphite treatment
Briefly, freshly harvested tissues were collected and submerged in 
Allprotect Tissue Reagent (Qiagen, USA) to stabilize DNA immedi-
ately and were stored in vials at 2–8°C for up to 6 months. DNA was 
extracted using the QIAamp DNA Mini Kit (Qiagen) according to the 
manufacturer’s recommendations.
EZ DNA Methylation- Gold™ Kit (Zymo Research, Orange, CA, USA) 
was used to treat 500 ng DNA (concentration 25 ng/μl) according to 
the manufacturer’s protocol. Bisulphite- treated DNA was eluted in 
300 μl of M- Elution Buffer.
2.4 | Analysis of DNA methylation
Analysis of DNA methylation was performed using previously 
published methods (Bollati et al., 2007; Tarantini et al., 2013) with 
minor modifications. Briefly, a 50 μl PCR reaction was carried out 
in 25 μl of GoTaq Hot Start Green Master Mix (Promega, Madison, 
WI, USA), 1 pmol of the forward primer, 1 pmol of the biotinylated 
reverse primer, 25 ng of bisulphite- treated genomic DNA and 
water. Primers used for DNA methylation analysis and PCR cycling 
conditions are shown in Table 1. The biotin- labelled primers were 
used to purify the final PCR product using Sepharose beads. The 
PCR product was bound to Streptavidin Sepharose HP (Amersham 
Biosciences, Uppsala, Sweden) and the Sepharose beads contain-
ing the immobilized PCR product were purified, washed, dena-
tured using a 0.2 mol/L NaOH solution and washed again using 
the Pyrosequencing Vacuum Prep Tool (Pyrosequencing Inc., 
Westborough, MA, USA), as recommended by the manufacturer. 
Then, 0.3 μl pyrosequencing primer was annealed to the purified 
single- stranded PCR product, and pyrosequencing was performed 
using the PyroMark MD System (Pyrosequencing Inc.). The degree 
of methylation was expressed as a percentage of methylated cy-
tosines divided by the sum of methylated and unmethylated cy-
tosines (%5 mC).
The CpG positions were selected according to data published in lit-
erature for the same assessed genes (Dawsey et al., 2008; Madrigano 
et al., 2012; Cantone et al., 2017), which ensures consistency in terms 
of repeatability of the assay.
2.5 | Statistical analysis
To compare gender and age distribution between the two groups, 
we use the chi- square and the Wilcoxon–Mann–Whitney test, 
respectively. To take into account correlations within subjects, 
random- intercept linear regression models were applied to evalu-
ate methylation levels across groups at baseline and to evaluate 
methylation changes over time in the periodontal disease group, 
separately for the disease- free and periodontitis sites. Statistical 
analyses were performed with Stata 13 (StataCorp. 2013; Rabe- 
Hesketh & Skrondal, 2008). Statistical significance was set at p- 
value <.05.
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3  | RESULTS
Twenty participants (8 males, 12 females) were included in this 
study, distributed into “healthy” (5 males, 5 females) and “periodontal 
disease” groups (3 males, 7 females). The age in the healthy group 
was between 25 and 69 years old (mean = 53.3 ± 12.3 years), while 
the range was 26–60 years old in the periodontal disease group 
(mean = 46.6 ± 10 years). Nineteen of the initial 20 participants com-
pleted the study with one dropout at the 8th week (Figure 1).
Periodontal therapy in the periodontal disease group was success-
ful based on the changes in the mean of PPD, CAL & BOP over time. 
Mean PPD at baseline was 4.2 ± 0.4 mm, which became 2.5 ± 0.3 mm 
on 8th week (p < .001). In the healthy group, PPD at baseline in all 
sites	was	≤3	mm.	Clinical	attachment	level	in	the	periodontitis	group	
was 4.2 ± 0.9 at baseline, indicating a moderate periodontal disease. 
Eight weeks post- therapy, mean CAL became 3.6 ± 0.9 mm (p = .01). 
As for bleeding on probing, mean percentage at baseline was 63% in 
periodontally diseased individuals and decreased up to 5% at the end 
of the evaluation period (p < .001).
Demographic and clinical characteristics of the study sample are 
shown in Table 2, while Table 3 reports clinical characteristics of the 
harvested sites in the periodontitis group at the time of biopsy. A 
marked improvement in PPD of periodontitis sites from which biop-
sies were harvested can be noted at 2 and 8 weeks (p < .001). Due 
to site selection characteristics, sites affected by periodontal disease 
must have had BOP at baseline while healthy sites in patients with 
periodontitis must not have had BOP at baseline. For 2 and 8 weeks 
point of time, BOP greatly reduced in all sites of the mouth follow-
ing periodontal therapy. Therefore, it was possible to harvest biopsies 
from sites that showed no BOP at these points of time, but had BOP 
at baseline as documented in the periodontal chart.
Regarding DNA methylation of TNF- α gene, the promoter re-
gion was more methylated in healthy individuals (36.6% ± 9.2), 
compared to normal & periodontitis sites of the periodontal disease 
group (34.1% ± 5.2 and 31.4% ± 7.8, respectively), indicating a rela-
tively more active gene expression of TNF- α in the state of disease. 
Methylation status remained almost stable in normal sites throughout 
the evaluation period. In the periodontitis sites, however, methylation 
level was almost stable up to 2 weeks. Afterwards, it started to rise 
reaching 33.7% ± 7.4 at 8 weeks, which is quite close to that reported 
in normal sites at baseline. Nonetheless, these results were not sta-
tistically significant (p- value > .05), neither among groups nor among 
sites.
As for the promoter region of IFN- γ gene, it was hypermethyl-
ated among all entities, with the healthy group displaying the high-
est methylation percentage among all (88.6% ± 1.4) reflecting a 
decreased gene expression of IFN- γ in the state of periodontal health. 
Regarding the periodontal disease group, the level of methylation 
in periodontitis sites was almost comparable to healthy individuals 
(88.3% ± 2.1), while normal sites exhibited a slightly lower methyla-
tion (85.8% ± 6.5). Through time, DNA methylation in periodontitis 
sites started to decline, reaching at 8 weeks a percentage almost 
equivalent to that reported in normal sites at baseline (86.2% ± 3.8). T
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On the other hand, methylation levels started to increase in normal 
sites, approaching a level at 8 weeks comparable to the healthy group 
(88.8% ± 2.8). None of these findings was statistically significant (p- 
value >.05).
3.1 | Periodontal therapy reduces the methylation of 
COX- 2 promoter
Unlike TNF- γ and IFN- γ, COX- 2 promoter region was hypometh-
ylated in periodontium of healthy patients (6.7% ± 7.6). DNA 
methylation was nearly as twice as high in the periodontitis sites 
(13.2% ± 7.3), while on normal tissues from patients with periodon-
tal disease, it was 8.8% ± 5.7. The discrepancy in the mean of meth-
ylation between periodontitis sites in comparison with healthy group 
at baseline was statistically significant (p = .03 for periodontitis sites 
versus healthy group). Following periodontal treatment, methylation 
percentage decreased dramatically in periodontitis sites, at 2 weeks, 
almost to half (5.8% ± 3.2, p < .001 versus baseline), with a very slight 
rise from 2 to 8 weeks (7.2% ± 4.3, p = .004 versus baseline), which 
was comparable to the methylation level reported in the healthy 
group. On the contrary, the mean percentage of methylation steadily 
declined in normal sites, reaching 5% ± 1.9 at 8 weeks, p = .03 versus 
baseline).
To evaluate the DNA methylation at a broader level, we explored 
the methylation profile of LINE- 1 promoter region. We observed 
that the mean percentage of methylation was similar between the 
healthy group (69.5% ± 3.5) and normal sites in diseased patients 
(69.4% ± 2.1) and remained fairly stable during the observation pe-
riod. As for periodontitis sites, a slight increase in the methylation of 
the promoter region at 8 weeks was observed (71.7% ± 2.8 versus 
70.2% ± 2.8 at baseline). These findings were not statistically signifi-
cant (p- value >.05).
Mean methylation percentages of the selected genes and p- values 
are summarized in Table 4. Time pattern of DNA Methylation among 
different groups for TNF- α, IFN- γ, COX- 2 and LINE- 1 are demon-
strated in Figure 2.
4  | DISCUSSION
Here, we provide for the first- time evidence of epigenetic modifications 
mediated by periodontal therapy. Due to the well- established association 
F IGURE  1 CONSORT flow diagram of 
the study population
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of methylation with stable gene regulation, we chose to evaluate the 
status of DNA methylation instead of the acetylation of genes related 
to inflammation (Bäckdahl et al., 2009). Our study shows the expression 
pattern of methylated genes before periodontal therapy and during the 
2 months follow- up. As alterations in the methylation patterns might 
vary from site to site within the same individual (Barros & Offenbacher, 
2014), we assessed the epigenetic modifications in normal and peri-
odontitis sites within the same patient with chronic periodontitis. We 
also compared our data to tissue samples from healthy periodontium. 
Our study gave emphasis to the methylation status of TNF- α, IFN- γ and 
COX- 2, as key genes associated with periodontal disease progression. 
We also carefully selected LINE- 1 gene as a genome- wide readout for 
methylation. Of note, our cohort of patients includes Caucasians, and 
careful interpretation of the results must take into consideration the 
potential ethnic influence over epigenetic modifications (Kwabi- Addo 
et al., 2010; Straughen, Sipahi, Uddin, Misra, & Misra, 2015).
Biopsy site At baseline
Two weeks after 
periodontal treatment
Eight weeks after 
periodontal treatment
PPD (mean ± SD)
Periodontal 
disease/normal 
sites
3.0 ± 0.0 2.8 ± 0.4 2.7 ± 0.5
p = .18 versus baseline p = .03 versus baseline
Periodontal 
disease/
periodontitis 
sites
7.1 ± 1.7 5.5 ± 0.8 4.4 ± 0.9
p < .001 versus 
normal sites
p < .001 versus baseline p < .001 versus baseline
CAL (mean ± SD)
Periodontal 
disease/normal 
sites
3.6 ± 0.8 3.6 ± 1.0 3.4 ± 1.9
p = 1.00 versus baseline p = .72 versus baseline
Periodontal 
disease/
periodontitis 
sites
8.4 ± 2.6 7.7 ± 2.5 5.6 ± 2.5
p < .001 versus 
normal sites
p = .23 versus baseline p < .001 versus baseline
p- values calculated with random- intercept linear regression models.
TABLE  3 Clinical characteristics of 
biopsied sites in the periodontitis group, at 
baseline, 2 and 8 weeks following 
periodontal therapy
Demographic/clinical 
characteristics Healthy (n = 10)
Periodontal disease 
(n = 10) p- valuea
Males/females 5/5 3/7 0.36
Age (years) 
(Mean ± SD)
53.3 ± 12.3 46.6 ± 10.0 0.11
Periodontal probing depth (mm) 
(Mean ± SD)
≤3	(at	baseline) 4.2 ± 0.4 (at baseline) ND
2.9 ± 0.4 (2 weeks after 
periodontal treatment)
p < .001
2.5 ± 0.3 (8 weeks after 
periodontal treatment)
p < .001
Clinical attachment level (mm)  
(Mean ± SD)
≤3 4.2 ± 0.9 (at baseline) ND
3.9 ± 1.2 (2 weeks after 
periodontal treatment)
p = .21
3.6 ± 0.9 (8 weeks after 
periodontal treatment)
p = .01
Bleeding on probing (%) 
(Mean ± SD)
0% 63 ± 25% (at baseline) ND
7 ± 6% (2 weeks after 
periodontal treatment)
p < .001
5 ± 6% (8 weeks after 
periodontal treatment)
p < .001
ND, not determined.
aFor gender and age, p- values were calculated by chi- squared and Wilcoxon–Mann–Whitney test, re-
spectively. For periodontal variables, p- values were obtained from random- intercept linear regression 
model.
TABLE  2 Patient demographic and 
clinical characteristics
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Findings of this study showed that periodontal therapy significantly 
reduced COX- 2 methylation levels comparable to healthy individuals at 
both 2 and 8 weeks after treatment. The methylation status of the COX- 2 
gene (also known as prostaglandin- endoperoxide synthase 2 or PTGS2) 
was inspected because it is the enzyme that synthesizes prostaglandin E2 
(PGE2) and governs its production. As is known, PGE2 is a key inflamma-
tory mediator in periodontal disease and is well correlated with periodon-
tal inflammation and alveolar bone loss (Goodson, Dewhirst, & Brunetti, 
1974; Noguchi & Ishikawa, 2007; Offenbacher et al., 1992; Reynolds, 
Prudencio, Aichelmann- Reidy, Woodward, & Uhrich, 2007; Tipton, Flynn, 
Stein, & Dabbous, 2003). We found that COX- 2 gene promoter was hy-
pomethylated in biopsies retrieved from the healthy group (6.7%), while 
DNA methylation was as twice higher in the periodontitis sites of the 
periodontal disease group (13.2%). Similarly, Loo, Jin, Cheung, Wang, and 
Chow (2010) described a hypermethylated COX- 2 in 19% of patients 
with chronic periodontitis. In concordance, Zhang, Barros, et al. (2010) 
identified a hypermethylated PTGS2 promoter in periodontal disease tis-
sues, associated with lower levels of PTGS2 transcription. Therefore, high 
Genes Group
Methylation percentage (Mean ± SD)
At baseline
Two weeks after 
periodontal treatment
Eight weeks after 
Periodontal treatment
TNF- α Healthy 36.6 ± 9.2 – –
Periodontal 
disease/
normal sites
34.1 ± 5.2 33.9 ± 6.5 34.0 ± 9.3
p = .44 
versus 
healthy
p = .92 versus baseline p = .90 versus baseline
Periodontal 
disease/
periodontitis 
sites
31.4 ± 7.8 31.5 ± 8.5 33.7 ± 7.4
p = .11 
versus 
healthy
p = .97 versus baseline p = .50 versus baseline
IFN- γ Healthy 88.6 ± 1.4 – –
Periodontal 
disease/
normal sites
85.8 ± 6.5 87.7 ± 3.5 88.8 ± 2.8
p = .10 
versus 
healthy
p = .33 versus baseline p = .14 versus baseline
Periodontal 
disease/
periodontitis 
sites
88.3 ± 2.1 88.4 ± 2.2 86.2 ± 3.8
p = .85 
versus 
healthy
p = .89 versus baseline p = .08 versus baseline
COX- 2 Healthy 6.7 ± 7.6 – –
Periodontal 
disease/
normal sites
8.8 ± 5.7 6.6 ± 3.6 5.0 ± 1.9
p = .47 
versus 
healthy
p = .18 versus baseline p = .03 versus baseline
Periodontal 
disease/
periodontitis 
sites
13.2 ± 7.3 5.8 ± 3.2 7.2 ± 4.3
p = .03 
versus 
healthy
p < .001 versus baseline p = .004 versus 
baseline
LINE- 1 Healthy 69.5 ± 3.5 – –
Periodontal 
disease/
normal sites
69.4 ± 2.1 70.0 ± 2.3 69.5 ± 1.4
p = .92 
versus 
healthy
p = .36 versus baseline p = .91 versus baseline
Periodontal 
disease/
periodontitis 
sites
70.2 ± 2.8 70.7 ± 2.8 71.7 ± 2.8
p = .58 
versus 
healthy
p = .61 versus baseline p = .22 versus baseline
p-values calculated with random-intercept linear regression models.
aThe sample size was 10 in each group- moment combinations, except for 8 weeks (one subject lost to 
follow- up).
TABLE  4 Methylation of LINE- 1, 
COX- 2, IFN- γ and TNF- α genes across 
groups and over timea
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levels of COX- 2 methylation can render an intrinsic protective mechanism 
capable of preventing the unrestrained breakdown of the periodontium 
(Zhang, Barros, et al., 2010). However, it must be noted that the methyla-
tion frequency of the COX- 2 gene promoter was much higher in our study 
than that reported by Zhang, Barros, et al. (2010); 6.7% versus 0.85% in 
the healthy sites and 13.2% versus 4.3% in the periodontitis- affected 
sites, as they measured DNA methylation of the COX- 2 gene promoter 
using a different technique, that is bisulphite specific PCR, cloning and 
sequencing.
Other findings in literature might further confirm the downregulation 
of COX- 2 in the state of chronic disease; in a previously published cross- 
sectional epidemiological study, the attachment level was negatively 
associated with the levels of PGE2 in the gingival crevicular fluid (GCF) 
(Zhong, Slade, Beck, & Offenbacher, 2007). Hence, it was suggested that 
chronic inflammation might serve as a new “set- point” in which certain 
inflammatory mediators are downregulated to prevent unrestricted de-
struction of periodontal tissues (Zhang, Barros, et al., 2010).
Regarding other biomarkers, findings of the present clinical investi-
gation revealed that periodontal therapy did not influence DNA methyl-
ation of TNF- α, IFN- γ and LINE- 1 levels at normal and periodontitis sites 
over time (p > .05), indicating that epigenetic alterations might be locally 
sustained for some mediators even after the elimination of periodontal 
inflammation. Nonetheless, certain observations can still be underlined; 
DNA methylation status of TNF- α gene promoter was almost stable in nor-
mal sites throughout the evaluation period and was not restored to that 
of the healthy group. This might indicate a different methylation profile 
in healthy tissues of individuals with and without history of periodontitis. 
Such information might help to better elucidate disease development in 
healthy sites in susceptible periodontitis patients, which needs to be fur-
ther investigated for implementing appropriate intervention plans (Mdala 
et al., 2014). However, this hypothesis needs to be confirmed in future 
studies exploring a wide panel of inflammatory cytokines. TNF- α gene 
was selected for DNA methylation analysis due to its important role in the 
pathogenesis of periodontal disease and tissue destruction (Page, 1991).
With respect to IFN- γ gene promoter, hypermethylation was evident 
among all entities even after periodontal therapy, which might be a usual 
feature in healthy and inflamed periodontal tissues. In fact, hypermethyl-
ation of IFN- γ gene promoter has already been reported in another study 
(Viana et al., 2011) probably due to the presence of distinctly active mixed 
cell population in the sample as previously suggested (Stefani et al., 2013; 
Winders, Schwartz, & Bruniquel, 2004). IFN- γ gene was evaluated in the 
present study because of its association with the severity and progression 
of periodontal disease (Garlet, Martins, Ferreira, Milanezi, & Silva, 2003).
For each gene, CpG positions were selected based on previously pub-
lished data (Dawsey et al., 2008; Madrigano et al., 2012; Cantone et al., 
2017), as they are more consistent in terms of repeatability of the assay. 
Four CpG islands were analysed for COX- 2 and TNF- α genes while two 
were assessed for IFN- γ gene. Although higher number of CpG islands 
was reported in literature for these genes (Zhang, Crivello, et al., 2010; 
Zhang, Barros, et al., 2010; Zhang et al., 2013), this can be attributed to 
the different technique utilized for DNA methylation analysis in the noted 
studies. Our clinical investigation is a pilot study, and with the limited 
F IGURE  2 Time pattern of DNA Methylation among different groups for TNF- α (a), IFN- γ (b), COX- 2 (c) and LINE- 1 (d). Circle represents 
healthy groups, intermittent line represents healthy sites in periodontitis group and solid line represents periodontitis sites in periodontitis group
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amount of available tissues, we were more interested in evaluating DNA 
methylation of more genes than covering the entire promoter of one single 
gene. Furthermore, we were not able to cover a larger sequence due to the 
limited amount of harvested tissues.
LINE- 1 was selected to evaluate the DNA methylation more com-
prehensively, as it encloses a high CpG density and comprises about 
17% of the genome (Kitkumthorn & Mutirangura, 2011; Newman et al., 
2012) with the total genomic methylation content being consistent with 
the methylation of such repetitive elements (Lange et al., 2012). Despite 
the lack of statistically significant findings, LINE- 1 hypermethylation was 
maintained in normal and periodontitis sites, overtime, reflecting an over-
all genome stability.
Based on the findings of the present study, we can conclude that: 
(i) periodontal therapy is not sufficient to reset the methylation levels of 
TNF- α and IFN- γ inflammatory genes to levels of healthy patients; (ii) peri-
odontal therapy is sufficient to reset the levels of COX- 2 methylation to 
compatible levels observed in healthy patients; (iii) the methylation pro-
file from normal tissues suggests that unaffected sites from patients with 
periodontal disease might be more prone to periodontal tissue break-
down; (iv) epigenetic modifications result in the activation of downregula-
tory mechanisms to prevent unrestricted periodontal tissue destruction; 
and finally (v) on a global methylation perspective, hypermethylation of 
LINE- 1 was maintained in periodontitis and normal sites, overtime.
The results of the study should be interpreted with caution as it has 
certain limitations. Gingival biopsies of normal and inflamed tissues were 
harvested from different sites and not the same one during different 
points of time. Sample collection from the same site is preferable when 
evaluating the influence of periodontal therapy over time, however, that 
was not possible because 2 weeks after periodontal therapy, soft tissues 
at the biopsy site were not completely healed. Another study limitation is 
the lack of longitudinal data on the healthy subjects as it only captured the 
temporal changes in the chronic periodontitis group; it was not possible 
to harvest multiple biopsies for healthy participants from an ethical stand-
point. Simultaneous analysis of DNA methylation and mRNA expression 
could have strengthened the consistency of our findings. However, the 
limited amount of tissue recovered from tissue biopsies, and the difficulty 
of collecting larger samples especially in control subjects did not allow for 
DNA and RNA analysis in the same subject. Also, limited numbers of CpG 
sites were analysed in our pilot study, despite being the same positions 
previously reported in literature. Hence, future studies are needed to 
allow us cover all the CpG sites within the promoter region.
Findings of this investigation represent data on the short- term; thus, 
epigenetic changes still need to be monitored on the long- term to under-
stand if the methylation status in chronic periodontitis could turn out sim-
ilar to that in healthy individuals with no history of periodontitis, following 
an effective periodontal therapy, maintenance and compliance.
5  | CONCLUSIONS
Periodontal therapy was able to reset the DNA methylation status 
of COX- 2 gene in patients with chronic periodontitis, while DNA 
methylation levels of TNF- α, IFN- γ and LINE- 1 were sustained in 
the periodontal disease group even after periodontal therapy. These 
findings suggest that the local effects of the disease have an influ-
ence on the epigenetics of the tissues that may be modulated by en-
vironmental factors, including the microbiota. Future investigations 
should further explore the identification of specific factors that affect 
the local epigenetics of periodontal soft and hard tissues. Moreover, 
future studies need to consider an expanded panel of inflammation- 
associated epigenetic changes over time in periodontal diseases.
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